search
Back to results

Testosterone Antidepressant Augmentation in Women

Primary Purpose

Depression

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Testosterone
Placebo
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression focused on measuring Depression, Major Depressive Disorder (MDD)

Eligibility Criteria

21 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Female, age 21-75
  2. Major depressive disorder including MADRS>/=12
  3. Currently treated with an antidepressant monotherapy (1st, 2nd or 3rd trial in current episode), that has been taken at an adequate dose for at least six weeks.

Exclusion Criteria:

  1. Serious suicide or homicide risk, as assessed by evaluating clinician
  2. Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic
  3. Substance use disorder active within last six months, or clinical suspicion of ongoing substance use disorder at the discretion of the study clinician at time of screening based on history and/or laboratory results.
  4. Any history of psychotic features, bipolar disorder, or primary obsessive compulsive disorder, as assessed by SCID
  5. Currently treated with typical or atypical antipsychotic medications, or lithium
  6. Untreated hypothyroidism. If treated hypothyroidism, change in levothyroxine dose within the prior 3 mos
  7. Use of androgens, including testosterone, dehydroepiandrosterone (DHEA) and methyltestosterone, within the prior three months
  8. Any investigational psychotropic drug within the last thirty days
  9. In the judgment of the study clinician, unlikely to be able to participate safely throughout the study period (three or more episodes of self-harm in the past year, documented history of poor treatment adherence, or frequent missed appointments (>50%) in the past year)
  10. ALT > 3x upper limit of normal or creatinine> 3x upper limit
  11. History of a hormone-responsive cancer

Sites / Locations

  • Massachusetts General Hospital
  • Butler Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Testosterone

Placebo

Arm Description

Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels.

Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks.

Outcomes

Primary Outcome Measures

Depressive Symptom Severity
Montgomery-Asberg Depression Rating Score (MADRS) Score: This scale measures depression symptom severity. Higher scores indicate more severe depression symptom severity. The score range is 0-60 units on a scale.

Secondary Outcome Measures

Fatigue
Brief Fatigue Inventory: This inventory measures fatigue severity. Higher scores indicate more severe fatigue. The range is 0-10 units on a scale.
Sexual Dysfunction
Derogatis Interview of Sexual Function (Total Score): This scale measures sexual function. Lower scores indicate worse sexual function. The score range for this questionnaire is 0-160.

Full Information

First Posted
February 1, 2013
Last Updated
May 3, 2018
Sponsor
Massachusetts General Hospital
Collaborators
National Institutes of Health (NIH), Lawley Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01783574
Brief Title
Testosterone Antidepressant Augmentation in Women
Official Title
Collaborative Study: Testosterone Antidepressant Augmentation in Women
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
August 2013 (Actual)
Primary Completion Date
January 27, 2017 (Actual)
Study Completion Date
January 27, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institutes of Health (NIH), Lawley Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators' hypotheses are: Low-dose testosterone augmentation improves depressive symptoms in women with Major Depressive Disorder (MDD) and antidepressant partial/nonresponse, adjunctive low-dose testosterone is safe and well-tolerated in women with MDD and antidepressant partial/nonresponse, and low-dose testosterone augmentation improves fatigue and sexual dysfunction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
Keywords
Depression, Major Depressive Disorder (MDD)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
101 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Testosterone
Arm Type
Active Comparator
Arm Description
Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks.
Intervention Type
Drug
Intervention Name(s)
Testosterone
Other Intervention Name(s)
AndroFeme 1(testosterone 1% w/v cream)
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Depressive Symptom Severity
Description
Montgomery-Asberg Depression Rating Score (MADRS) Score: This scale measures depression symptom severity. Higher scores indicate more severe depression symptom severity. The score range is 0-60 units on a scale.
Time Frame
Week 8
Secondary Outcome Measure Information:
Title
Fatigue
Description
Brief Fatigue Inventory: This inventory measures fatigue severity. Higher scores indicate more severe fatigue. The range is 0-10 units on a scale.
Time Frame
Week 8
Title
Sexual Dysfunction
Description
Derogatis Interview of Sexual Function (Total Score): This scale measures sexual function. Lower scores indicate worse sexual function. The score range for this questionnaire is 0-160.
Time Frame
Week 8

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female, age 21-75 Major depressive disorder including MADRS>/=12 Currently treated with an antidepressant monotherapy (1st, 2nd or 3rd trial in current episode), that has been taken at an adequate dose for at least six weeks. Exclusion Criteria: Serious suicide or homicide risk, as assessed by evaluating clinician Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic Substance use disorder active within last six months, or clinical suspicion of ongoing substance use disorder at the discretion of the study clinician at time of screening based on history and/or laboratory results. Any history of psychotic features, bipolar disorder, or primary obsessive compulsive disorder, as assessed by SCID Currently treated with typical or atypical antipsychotic medications, or lithium Untreated hypothyroidism. If treated hypothyroidism, change in levothyroxine dose within the prior 3 mos Use of androgens, including testosterone, dehydroepiandrosterone (DHEA) and methyltestosterone, within the prior three months Any investigational psychotropic drug within the last thirty days In the judgment of the study clinician, unlikely to be able to participate safely throughout the study period (three or more episodes of self-harm in the past year, documented history of poor treatment adherence, or frequent missed appointments (>50%) in the past year) ALT > 3x upper limit of normal or creatinine> 3x upper limit History of a hormone-responsive cancer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen Miller, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maurizio Fava, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Linda L Carpenter, MD
Organizational Affiliation
Butler Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Butler Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02906
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
32660299
Citation
Dichtel LE, Carpenter LL, Nyer M, Mischoulon D, Kimball A, Deckersbach T, Dougherty DD, Schoenfeld DA, Fisher L, Cusin C, Dording C, Trinh NH, Pedrelli P, Yeung A, Farabaugh A, Papakostas GI, Chang T, Shapero BG, Chen J, Cassano P, Hahn EM, Rao EM, Brady RO Jr, Singh RJ, Tyrka AR, Price LH, Fava M, Miller KK. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry. 2020 Oct 1;177(10):965-973. doi: 10.1176/appi.ajp.2020.19080844. Epub 2020 Jul 14.
Results Reference
derived

Learn more about this trial

Testosterone Antidepressant Augmentation in Women

We'll reach out to this number within 24 hrs